{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T16:10:42Z","timestamp":1779120642343,"version":"3.51.4"},"reference-count":42,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Venous thromboembolism (VTE) is a serious complication frequently encountered in cancer patients and is associated with high morbidity. In patients undergoing cancer treatment\u2014particularly those receiving chemotherapy\u2014VTE increases treatment-related complications and has a direct impact on mortality. The development of VTE in oncology patients varies depending on cancer type, treatment protocols, and individual patient characteristics. The Khorana Risk Score (KRS) is a validated risk assessment tool used to estimate the risk of VTE development in patients receiving chemotherapy. KRS provides risk estimations based on the patient\u2019s clinical features, cancer type, and treatment process. This study aims to investigate the prognostic value of the Khorana Risk Score in predicting VTE development and overall survival in patients with metastatic gastric cancer. Materials and Methods: This retrospective study used data from 337 metastatic gastric cancer patients who presented to Kartal Dr. L\u00fctfi K\u0131rdar City Hospital between January 2012 and June 2024. Patients were categorized into intermediate- and high-risk groups according to the Khorana Risk Score. The study\u2019s primary endpoints were the development of VTE and overall survival. Results: There was no statistically significant difference in VTE incidence (p = 0.27) or overall survival (11.9 months vs. 11.5 months, p = 0.23) between patients in the intermediate- and high-risk groups. Conclusions: These results indicate that the Khorana Risk Score is insufficient in predicting VTE development in patients with metastatic gastric cancer and has a weak association with overall survival outcomes. In conclusion, this study demonstrates the KRS\u2019s inadequacy in predicting VTE and survival outcomes in patients with metastatic gastric cancer, highlighting the need for more tailored approaches.<\/jats:p>","DOI":"10.3390\/medicina61061075","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T08:18:06Z","timestamp":1749629886000},"page":"1075","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Association of Khorana Risk Score with Venous Thromboembolism and Overall Survival in Patients with Metastatic Gastric Cancer"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3846-7047","authenticated-orcid":false,"given":"Ezgi","family":"Turkoglu","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Health Science University, Kartal Dr. L\u00fctfi Kirdar City Hospital, 34865 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6221-0623","authenticated-orcid":false,"given":"Goncagul Akdag","family":"Topal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokat State Hospital, 60100 Tokat, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2423-6902","authenticated-orcid":false,"given":"Sedat","family":"Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Health Science University, Kartal Dr. L\u00fctfi Kirdar City Hospital, 34865 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5983-3291","authenticated-orcid":false,"given":"Oguzcan","family":"K\u0131n\u0131koglu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Health Science University, Kartal Dr. L\u00fctfi Kirdar City Hospital, 34865 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5863-3511","authenticated-orcid":false,"given":"Nisanur","family":"Sar\u0131yar Busery","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Health Science University, Kartal Dr. L\u00fctfi Kirdar City Hospital, 34865 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tugba","family":"Kaya","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Health Science University, Kartal Dr. L\u00fctfi Kirdar City Hospital, 34865 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hacer Sahika","family":"Y\u0131ld\u0131z","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Health Science University, Kartal Dr. L\u00fctfi Kirdar City Hospital, 34865 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Furkan","family":"Turkoglu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Aktif International Hospital, 41275 Kocaeli, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cihad","family":"Tatar","sequence":"additional","affiliation":[{"name":"Private Practice, 34000 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2538-8569","authenticated-orcid":false,"given":"Abdullah","family":"Sakin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Bahcelievler Medipol Hospital, 34196 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4398-5148","authenticated-orcid":false,"given":"Deniz","family":"Is\u0131k","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Health Science University, Kartal Dr. L\u00fctfi Kirdar City Hospital, 34865 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7555-2657","authenticated-orcid":false,"given":"Seval","family":"Ay Ersoy","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Health Science University, Kartal Dr. L\u00fctfi Kirdar City Hospital, 34865 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tugba","family":"Basoglu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Health Science University, Kartal Dr. L\u00fctfi Kirdar City Hospital, 34865 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5757-4705","authenticated-orcid":false,"given":"Hatice","family":"Odabas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Health Science University, Kartal Dr. L\u00fctfi Kirdar City Hospital, 34865 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1140-8779","authenticated-orcid":false,"given":"Nedim","family":"Turan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Health Science University, Kartal Dr. L\u00fctfi Kirdar City Hospital, 34865 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1470-2045(22)00704-5","article-title":"Cancer survival in Africa, central and south America, and Asia (SURVCAN-3): A population-based benchmarking study in 32 countries","volume":"24","author":"Soerjomataram","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1055-9965.EPI-16-0520","article-title":"Cancer Incidence and Survival Trends by Subtype Using Data from the Surveillance Epidemiology and End Results Program, 1992\u20132013","volume":"26","author":"Noone","year":"2017","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00520-013-1742-6","article-title":"Thromboembolic disease in cancer patients","volume":"21","author":"Hindi","year":"2013","journal-title":"Support. Care Cancer"},{"key":"ref_5","first-page":"e7883","article-title":"Validation of the Khorana Score to Assess Venous Thromboembolism and Its Association with Mortality in Cancer Patients: A Retrospective Community-based Observational Experience","volume":"12","author":"Ahmed","year":"2020","journal-title":"Cureus"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e072715","DOI":"10.1136\/bmj-2022-072715","article-title":"Prevention of venous thromboembolism in patients with cancer","volume":"381","author":"Guntupalli","year":"2023","journal-title":"BMJ"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3109\/10428194.2010.551572","article-title":"Concomitant and antecedent deep venous thrombosis and cancer survival in male US veterans","volume":"52","author":"Anderson","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/sj.bjc.6605883","article-title":"Hospitalisation for venous thromboembolism in cancer patients and the general population: A population-based cohort study in Denmark, 1997\u20132006","volume":"103","author":"Pedersen","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1182\/bloodadvances.2021006484","article-title":"Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy","volume":"6","author":"Overvad","year":"2022","journal-title":"Blood Adv."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: ASCO Clinical Practice Guideline Update","volume":"38","author":"Key","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1634\/theoncologist.2017-0205","article-title":"Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK)","volume":"23","author":"Kuderer","year":"2018","journal-title":"Oncologist"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.thromres.2018.01.036","article-title":"Risk prediction of cancer-associated thrombosis: Appraising the first decade and developing the future","volume":"164","author":"Khorana","year":"2018","journal-title":"Thromb. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1634\/theoncologist.2015-0361","article-title":"A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality","volume":"21","author":"Kuderer","year":"2016","journal-title":"Oncologist"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1177\/1076029618777153","article-title":"Khorana Score: \u039dew Predictor of Early Mortality in Patients with Lung Adenocarcinoma","volume":"24","author":"Vathiotis","year":"2018","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.thromres.2012.08.285","article-title":"Tissue factor and cancer","volume":"130","author":"Ruf","year":"2012","journal-title":"Thromb. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s11239-025-03086-2","article-title":"Khorana risk score in lung cancer patients treated with immune checkpoint inhibitors: A real-world study","volume":"58","author":"Song","year":"2025","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3892\/mco.2024.2771","article-title":"Analysis of thromboembolism and prognosis in metastatic pancreatic cancer from the Tokushukai REAl-world data project","volume":"21","author":"Shimoyama","year":"2024","journal-title":"Mol. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"pkx009","DOI":"10.1093\/jncics\/pkx009","article-title":"Clinical Predictors of Early Mortality in Colorectal Cancer Patients Undergoing Chemotherapy: Results from a Global Prospective Cohort Study","volume":"1","author":"Sohal","year":"2017","journal-title":"JNCI Cancer Spectr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.4251\/wjgo.v15.i10.1784","article-title":"Association between the Khorana risk score and all-cause mortality in Japanese patients with gastric and colorectal cancer: A retrospective cohort study","volume":"15","author":"Zhang","year":"2023","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/jth.13378","article-title":"Predictors of active cancer thromboembolic outcomes: Validation of the Khorana score among patients with lung cancer","volume":"14","author":"Mansfield","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"101156","DOI":"10.1016\/j.gore.2023.101156","article-title":"Use of the Khorana score to predict venous thromboembolism in patients undergoing chemotherapy for uterine cancer","volume":"46","author":"Piver","year":"2023","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.thromres.2016.12.013","article-title":"The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer","volume":"150","author":"Franke","year":"2017","journal-title":"Thromb. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1007\/s00432-021-03590-x","article-title":"Early venous thromboembolism is a strong prognostic factor in patients with advanced pancreatic ductal adenocarcinoma","volume":"147","author":"Barrau","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/archinte.166.4.458","article-title":"Incidence of venous thromboembolism and its effect on survival among patients with common cancers","volume":"166","author":"Chew","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1200\/JCO.2007.14.1283","article-title":"American Society of Clinical Oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer","volume":"25","author":"Lyman","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1200\/JCO.2012.42.6635","article-title":"Prognostic significance of signet ring gastric cancer","volume":"30","author":"Taghavi","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Kersy, O., Loewenstein, S., Lubezky, N., Sher, O., Simon, N.B., Klausner, J.M., and Lahat, G. (2019). Omental Tissue-Mediated Tumorigenesis of Gastric Cancer Peritoneal Metastases. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01267"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.it.2017.03.002","article-title":"Immunological Functions of the Omentum","volume":"38","author":"Randall","year":"2017","journal-title":"Trends Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1055\/s-0042-1751096","article-title":"Occult Omental Metastasis in Gastric Adenocarcinoma: An Analysis of Incidence, Predictors, and Outcomes","volume":"11","author":"Paul","year":"2022","journal-title":"South Asian J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Zhang, H., Cheng, X., Guo, W., Zheng, C., Zhang, Y., Jing, X., and Qiao, H. (2024). Metastasis patterns and prognosis in young gastric cancer patients: A propensity score-matched SEER database analysis. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0301834"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/ajco.13025","article-title":"Metastatic gastric cancer: Does the site of metastasis make a difference?","volume":"15","author":"Tan","year":"2019","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.2005.05.0245","article-title":"Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data","volume":"24","author":"Wagner","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Chen, X.L., Chen, X.Z., Yang, C., Liao, Y.B., Li, H., Wang, L., Yang, K., Li, K., Hu, J.K., and Zhang, B. (2013). Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: A systematic review and meta-analysis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060320"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1200\/JCO.23.01601","article-title":"First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial","volume":"42","author":"Janjigian","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): A multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","article-title":"Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials","volume":"7","author":"Chao","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jacasi.2021.07.006","article-title":"Validation of the Khorana Venous Thromboembolism Risk Score in Japanese Cancer Patients","volume":"1","author":"Sueta","year":"2021","journal-title":"JACC Asia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jjcc.2021.11.024","article-title":"Evaluating the Khorana risk score of gastrointestinal cancer patients during initial chemotherapy as a predictor of patient mortality: A retrospective study","volume":"79","author":"Shibata","year":"2022","journal-title":"J. Cardiol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/6\/1075\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:50:04Z","timestamp":1760032204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/6\/1075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["medicina61061075"],"URL":"https:\/\/doi.org\/10.3390\/medicina61061075","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,11]]}}}